Floatz logo

Vyxeos

Refractory Pediatric AML

Princess Maxima Center for Pediatric OncologyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Refractory Pediatric AML cohort.

Asset / SponsorPhaseRating
Ifosfamide
Samsung Medical Center
Phase 2CCC
gw786034
Samsung Medical Center
Phase 2CCC
Imatinib
Samsung Medical Center
Phase 2CCC
TRASTUZUMAB
Samsung Medical Center
Phase 2CCC
Axitinib
Samsung Medical Center
Phase 2CCC

View all 10 →

Same molecule, other indications

Vyxeos is also rated in:

myelodysplastic syndromeDormant
B
Indicative ·
57 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
56 / 100
View asset →
childhood acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →